Pharma News

RP-3 by Replimune for Lung Cancer: Likelihood of Approval

Photo of MEEFRO MEEFRO Send an email November 17, 2023
0 0 Less than a minute

RP-3 is under clinical development by Replimune and currently in Phase I for Lung Cancer.

Source link
#RP3 #Replimune #Lung #Cancer #Likelihood #Approval

Photo of MEEFRO MEEFRO Send an email November 17, 2023
0 0 Less than a minute
Photo of MEEFRO

MEEFRO

Related Articles

What is the current valuation of AstraZeneca’s Sabestomig

April 16, 2024

What is the current valuation of AbbVie’s ABBV-400

April 16, 2024

What is the current valuation of Merck’s MK-1084

April 16, 2024

What is the current valuation of AstraZeneca’s AZD-9574

April 16, 2024

Leave a Reply

Your email address will not be published. Required fields are marked *